CAPE TOWN, SA / ACCESSWIRE / May 24, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update:

The company is pleased to announce the appointment of Robert Simbowe as Director of Health and Fitness.

Robert is a professional MMA fighter with the Extreme Fighting Championship (EFC), the largest MMA promotion company on the African continent that features professional fighters from around the world. He is commonly known as the "Black Tiger" in the MMA world for his patience and pounce and strike style. Robert will be a full-time ambassador for the company's products.

Robert Simbowe said, "The science behind the medicinal properties of CBD, cannabis and psychedelics has been something I have developed a keen interest towards. MMA fighting is one of the toughest sports in the world. The fighting and training results in frequent soreness, inflammation, sleep disorders, concussions and a lot more that we must regularly recover from to stay healthy. CBD has been a far superior substitute to opioids and other substances as it is not addictive. It also helps improve the quality of our sleep - one of the most important things for mental and physical recovery. MMA fighter or not, everyone can benefit from CBD's anti-inflammatory, antispasmodic and sleep-aiding properties. The work done by M2Bio Sciences (WGG) is extremely relevant and has so much potential to drastically improve everyone's well-being. My experience with the company's CBD balms, capsules, oils and beverages has been amazing. I am very excited to do my part in raising global awareness for the company and passionately take its health and fitness mission forward."

"Robert's experience in MMA has led him to gain immense knowledge about health and fitness over the years. His dedication to this space is so inspiring, we are thrilled to have him join the team" said Wuhan General Group CEO, Jeff Robinson.

About Wuhan General Group, Inc./ M₂Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, Liviana™ and Handcrafted Delights™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "WUHN".

Publicly traded company (OTC Pink: WUHN)

Website: www.m2bio.co
E-mail:info@m2bio.co

Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/m2bio

Forward-Looking Statements:

Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./M₂Bio Sciences, Inc.